HomeAI · summaries
Storia in 2 fonti
Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend
Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Apollo Hospitals Q4 Results: Cons PAT jumps 36% YoY to Rs 529 crore, revenue rises 18%; Rs 10 per share dividend declared
Apollo Hospitals reported strong Q4 FY26 results: consolidated PAT surged 36% YoY to Rs 529 crore, and revenue increased 18% to Rs 6,605 crore. EBITDA grew 31% to Rs 1,011 crore.…
- ·
Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?
Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages…
- ·
Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend
Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore…
- ·
thehindubusinessline.com
Sun Pharma Q4 net profit up 26% at ₹2,714 crore
Sun Pharma's Q4 net profit rises 26% to ₹2,714 crore, driven by robust formulation sales and strong overall revenue growth.
- ·
Sun Pharma Q4 net profit up 26 per cent
Sun Pharma reports a 26% rise in Q4 net profit, driven by strong sales and ongoing investments in innovative products.
- ·
Margin pressure, slower growth outlook may cap upside for Sun Pharma stock
Sun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and lower milestone income. The company…